U.S. Reneo Pharma closes $50 million Series A round led by NEA

05/21/2019 2:39:00 PM (GMT)

California-based Reneo Pharmaceuticals, a clinical-stage pharmaceutical company, has secured $50 million in a Series A funding.

U.S. venture capital firm New Enterprise Associates (NEA) led the funding round with participation from Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners.

Reneo Pharmaceuticals will use the new funds to develop therapies for diseases associated with deficits in cellular metabolism and energy production.

Additionally, the company will also use the money raised from the funding to support the ongoing Phase 1b clinical trials as well as other clinical and preclinical studies.

Reneo Pharmaceuticals

All success stories are prepared by Investsize editors which is selecting elite and remarkable information from press releases and anonymous news sources.There is no charge applied for any success stories which is published . Those published success stories are not investment advices and doesnt offer recommendations Alternate Text